Primaquine in vivax malaria: an update and review on management issues

Malaria Journal

Review

Senaka Rajapakse¹  Chaturaka Rodrigo¹  Deepika Fernando² 

[1] Department of Clinical Medicine, Faculty of Medicine, Colombo, Sri Lanka;Department of Parasitology, Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo 8, Sri Lanka;

关键词: Primaquine;    Plasmodium vivax;    Vivax Malaria;    Prophylaxis;    Radical cure;   

DOI  :  10.1186/1475-2875-10-351

 received in 2011-09-21, accepted in 2011-12-12,  发布年份 2011

来源: Springer

【 摘 要 】

Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.

【 授权许可】

CC BY   
© Fernando et al; licensee BioMed Central Ltd. 2011